Orphan Therapies for Rare Diseases

Helping small patient populations maximize the benefits of therapies for rare diseases requires a partner with specialized knowledge and an exceptional level of support. We understand the unique commercialization challenges for orphan therapies and provide program solutions that improve patient access, engagement and outcomes.  

Exceptional Level of Partnership and Customization: As an independent pharmacy, US Bioservices has the ability to be fully accessible, responsive and flexible in our partnerships and program design. We understand that rare diseases vary greatly and span a broad range of disorders. We partner with you to develop custom, high-touch services that are tailored to the unique needs of the patient population.   

Stable Ownership: As part of AmerisourceBergen, partners benefit from the resources and infrastructure of a Fortune 11 company.  When you select US Bioservices, you are choosing a stable business partner, without making the compromises that can arise within larger distribution channels. 

Thought Leadership: Because there is often limited information about a rare condition, patients may experience diagnosis delays or misdiagnosis resulting in access challenges and financial burdens. As a specialty pharmacy supporting successful exclusive and limited distribution networks, we offer partners guidance and best practices for engaging prescribers, payers, patients and other key stakeholders to improve access and adherence.

Specialized Expertise and Dedicated Program Teams: We understand that a unique therapy for a rare condition requires our associates and clinicians to develop deep, specialized expertise to offer exceptional support.  We understand that rare disease symptoms not only vary by disease, but also from patient to patient with the same disease. Our model supports dedicated program teams focused exclusively on your therapy to offer the highest level of patient support and specialization.

Patient Access to Therapy:  Reimbursement challenges may arise for orphan products that are difficult to navigate. US Bioservices has experience and success in rapidly establishing in-network patient access and coverage for new therapies through contract amendments, letters of agreement and new limited distribution agreements.   

Transparency: The level of transparency that we provide through our operational and technology solutions sets us apart. Greater visibility and collaboration is needed for programs with small patient populations. In addition to our dedicated program teams, we offer superior clinical analytics and portal technology, which can include integration with your systems, providing real-time, detailed updates about each patient.

Actionable Clinical Analytics: Excellent analytics are essential for program optimization. In addition to our comprehensive standard suite of reports, we can recommend custom analytics that are tailored to the unique aspects of your program.

REMS: US Bioservices is experienced in dispensing therapies with REMS.  We work with our partners to design operational processes and data collects to ensure all REMS requirements are stored, tracked and reported using our pharmacy management system.